Archive for June, 2014

(SMSI) New AniMates App Adds ‘Character’ to Mobile Messaging

Smith Micro’s Latest Android App Opens New World of Visual Messaging Personas With Award-Winning Animation Technology and Content Creators

ALISO VIEJO, CA–(Jun 30, 2014) – Smith Micro Software, Inc. (NASDAQ: SMSI) today announced its new AniMates™ mobile messaging app that lets users personalize voice messages with talking characters, scenic backgrounds and voice effects. Built using Smith Micro’s award-winning animation software, AniMates offers a wide range of content from world-renowned digital artists, allowing users to express themselves through multiple personas. It also breaks down the walled-garden of traditional messaging platforms by letting users share messages with anyone.

“AniMates represents a unique combination of our core competencies in 2D/3D digital design software and carrier-grade mobile messaging, bringing a compelling new experience to the Android market,” said William W. Smith, Jr., CEO at Smith Micro. “But what really makes AniMates unique is the content — we’re cultivating a fantastic library of characters and backgrounds from an artist community of thousands who have used our animation software for years. There will be no limit to the creativity and diversity that users will be able to enjoy with AniMates characters.”

AniMates was collaboratively developed by engineering teams from Smith Micro’s CommSuite® carrier-grade messaging platform and its award-winning Anime Studio® animation software. Key features of AniMates include:

  • Sending and receiving talking character messages for free
  • Diverse content library offering dozens of characters and backgrounds, with new content added every week
  • Ability to use your own photo background from the phone gallery
  • Optional voice effects with variable pitch control
  • See and manage messages from other AniMates users through an inbox view
  • Share messages with anyone via email, SMS or Facebook
  • Easily access contacts through the phone address book
  • Extend recording time to 2 minutes with premium upgrade

“The problem with messaging apps today is you have to download a dozen of them to communicate with your entire network of friends, family, colleagues, etc., who are all using different apps with varying levels of personalization. We wanted to address that problem in two ways: first, AniMates users can send messages to anyone so your contacts don’t have to install the app to view messages; second, AniMates can be bundled into other messaging apps, allowing developers to provide a rich, diverse library of content from their own platforms so users can express themselves wherever and however they like,” said Vinay Chandra, Vice President of Product Management at Smith Micro.

“We’re incredibly proud to have top-notch digital artists creating AniMates content using our animation products. These are people who design for Disney, Cartoon Network, Nickelodeon, and major retail brands, and they believe in our vision for AniMates as the ultimate in personalized, fun, easy-to-share mobile messaging,” said Steve Yatson, Vice President of Productivity and Graphics Solutions at Smith Micro. “But the key to engaging communities globally is offering localized content, which we will achieve by opening up content creation to digital artists worldwide. Our goal is to harness the talent of millions of users of our animation tools to create a content library that is unequaled in the industry.”


AniMates is available now on the Google Play™ store for mobile users in the U.S. and Canada. The app comes with five free characters and five free backgrounds, with premium content available for purchase. In the coming months, Smith Micro will begin offering content bundles that include theme-based characters and backgrounds.

AniMates for iOS will be available in late July. Smith Micro also plans to expand the app to other countries and languages later this year.

Learn more about AniMates and see sample messages.

About Smith Micro Software, Inc.:
Smith Micro Software provides solutions that simplify, secure and enhance the mobile experience. Our portfolio includes a wide range of applications that manage broadband connectivity, data traffic, devices, voice and video communications over wireless networks. With more than 30 years of experience developing world-class client and server software, Smith Micro helps the leading mobile network operators, device manufacturers and enterprises increase efficiency and capitalize on the growth of mobile-connected consumers and workforces. For more information, visit (NASDAQ: SMSI)

Safe Harbor Statement:
This release may contain forward-looking statements that involve risks and uncertainties including, without limitation, forward-looking statements relating to the company’s financial prospects and projections, the company’s ability to increase its business, and the anticipated timing and financial performance of new products. Among the important factors that could cause actual results to differ materially from those in the forward-looking statements are new and changing technologies, customer acceptance of those technologies, fluctuations or cancellations in orders from customers, new and continuing adverse economic conditions, and the company’s ability to compete effectively with other software companies. These and other factors discussed in the company’s filings with the Securities and Exchange Commission, including its filings on Forms 10-K and 10-Q, could cause actual results to differ materially from those presented in any forward-looking statements. Smith Micro assumes no obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Smith Micro, AniMates and the Smith Micro logo are registered trademarks or trademarks of Smith Micro Software, Inc. All other trademarks and product names are the property of their respective companies.

Suzanne Runald
Smith Micro Software, Inc.
+1 (949) 362-5800
Email Contact

Evie Carter
FortyThree PR for Smith Micro
+1 (831) 401-3175
Email Contact

Monday, June 30th, 2014 Uncategorized Comments Off on (SMSI) New AniMates App Adds ‘Character’ to Mobile Messaging

(HART) HART-Trachea Spotlighted in NBC-TV News Special

Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, announces its HART-Trachea was spotlighted in a two-hour-long NBC-TV News Special on Friday, June 27.

Titled “A Leap of Faith: A Meredith Vieira Special,” the program focuses on the accomplishments of Dr. Paolo Macchiarini of Karolinska University Hospital and Karolinska Institutet in Huddinge, Stockholm, who has performed several trachea transplant surgeries that were made possible in part by the use of HART’s technology.

To view the NBC special in its entirety, please visit the following link:

To view Ms. Vieira’s interview with David Green, CEO of HART, about how the HART-Trachea is made, please visit:

The videos at the links above are provided for informational purposes only. Harvard Apparatus Regenerative Technology, Inc. is not responsible for the content of the linked videos.

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product, the HART-Trachea, is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma. Our technology has been used in eight human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. On November 1, 2013, HART was spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.

Forward-Looking Statements

Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements include statements relating to, among other things, the planned commercialization efforts and marketing approvals of HART’s products as well as the success thereof and the availability of a market for the HART securities. These statements involve risks and uncertainties, including among other things, market conditions that may cause results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Apparatus Regenerative Technology expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Monday, June 30th, 2014 Uncategorized Comments Off on (HART) HART-Trachea Spotlighted in NBC-TV News Special

(TWOU) Teams Up With Pencils of Promise to Help Build Schools in Guatemala

2U’s Charitable Initiative Reaffirms its Mission to Support Education Around the World

LANDOVER, Md., June 30, 2014  — 2U, Inc. (NASDAQ: TWOU), a leading provider of cloud-based software-as-a-service solutions for leading nonprofit colleges and universities to deliver high-quality education to qualified students anywhere, today announced a new charitable initiative with Pencils of Promise (PoP), a for-purpose nonprofit organization that has built more than 200 schools for children across Africa, Asia and Latin America. Through the initiative, 2U and its employees will raise funds to bring life-changing education to children in Guatemala by supporting PoP’s efforts to build schools, train teachers and provide scholarships.

“At 2U, we believe meaningful education outcomes can be achieved anywhere,” said Chip Paucek, CEO and co-founder of 2U. “After meeting Adam Braun and learning about Pencils of Promise, I’ve been so impressed by the work they’re doing to ensure that educational opportunities are available to communities throughout the world. I’m so happy that 2U and our employees will support this vital cause, making access to education a reality for children in Guatemala.”

“Our Pencils of Promise partners are more like family. Joining together with Chip and 2U was especially exciting to me, as we share a fundamental mission to provide educational opportunities for students around the world, whether they be children in Guatemala or graduate students in the Middle East,” said Adam Braun, founder of Pencils of Promise. “We couldn’t be more pleased to have the 2U family join us as we work to serve more students than ever before.”

2U will send a group of employees to Guatemala to join in the construction of PoP schools sponsored by 2U. 2U employees around the globe will participate in the initiative, representing offices in Landover, Md.; New York; Los Angeles; Chapel Hill, N.C.; and Hong Kong.

About 2U, Inc. (NASDAQ: TWOU)
Founded in 2008 by a team of education and technology veterans, 2U enables leading colleges and universities to deliver their high-quality education to qualified students anywhere. Our cloud-based software-as-a-service platform provides schools with the comprehensive operating infrastructure they need to attract, enroll, educate, support and graduate their students. Our mission is to enable the education our clients provide to reach its highest potential so students can reach theirs. To learn more, go to

About Pencils of Promise:
Pencils of Promise (“PoP”) is a nonprofit organization founded in 2008 to increase access to quality education for children in the developing world. PoP works with communities across the globe to build schools and create programs that provide education opportunities for children, no matter where they were born, or what resources they have.  PoP has broken ground on over 200 schools throughout Laos, Nicaragua, Guatemala, and Ghana, and has established itself as a leader amongst the innovative global nonprofits working toward sustainable social change.  For more information, please visit, like us at, or follow us at @PencilsOfPromis

Media Inquiries:

Pencils of Promise
Cristin Klein | | 212.691.2800
Alexandra Barnett | | 212.691.2800

2U, Inc.
Shirley Chow

Monday, June 30th, 2014 Uncategorized Comments Off on (TWOU) Teams Up With Pencils of Promise to Help Build Schools in Guatemala

(FOLD) Updates and Final Analysis Plan for Phase 3 Fabry Monotherapy Study 012

Last Patient Completes 18-Month Primary Treatment Period – Top-Line Data on Track to Report in 3Q14

96% of Patients with Amenable Mutations Elected to Continue in 12-Month Treatment Extension

Statistical Analysis Plan Finalized

CRANBURY, N.J., June 30, 2014  — Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today provided updates and detailed the statistical analysis plan for its second Phase 3 study (Study 012) of the oral small molecule pharmacological chaperone migalastat HCl (“migalastat”) monotherapy for Fabry patients with amenable mutations. The 18-month primary treatment period is now complete and top-line data from Study 012 are expected in the third quarter of 2014. If successful, Study 012 will trigger the process for European regulatory approval of migalastat as a monotherapy for Fabry patients with amenable mutations.

Study 012 is the first clinical study to compare oral migalastat to standard-of-care enzyme replacement therapies (ERTs) for Fabry disease (Fabrazyme® and Replagal®). The primary outcome measure is renal function at 18 months. This open-label registration study enrolled 60 patients (26 males and 34 females) with Fabry disease with amenable mutations who had been treated with ERT for a minimum of 12 months prior to study entry. These patients were randomized 1.5:1 to switch to migalastat (36 patients) or remain on ERT (24 patients) for the primary 18-month treatment period, after which they were eligible to receive migalastat in a 12-month extension phase. Among the 60 patients enrolled, 56 (34 in the migalastat group and 22 in the ERT group) had amenable mutations in a GLP-validated human embryonic kidney (HEK) cell-based in vitro assay (“GLP HEK amenable”).

Study 012 (The ATTRACT Study, or AT1001-012) Patient Disposition Highlights

  • Following randomization, 34 of 36 patients who switched to migalastat and 18 of 24 patients who continued with ERT completed the primary 18-month treatment period.
  • Among patients completing the 18-month primary treatment period, 32 out of 34 in the migalastat group and 16 out of 18 in the ERT group had GLP HEK amenable mutations.
  • 97% of patients with GLP HEK amenable mutations in the migalastat group (31 out of 32) elected to continue to receive migalastat in the 12-month treatment extension.
  • 94% of patients with GLP HEK amenable mutations in the ERT group (15 out of 16) elected to switch from ERT to migalastat for the 12-month treatment extension.

John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “We are very pleased to be advancing our Fabry monotherapy chaperone program into the final stages of drug development for Fabry patients with amenable mutations. Following on the heels of our recent positive results from our first Phase 3 registration Study 011, we are on track to report data in the third quarter of this year from Study 012, in which patients have volunteered to switch from ERT to our oral chaperone migalastat as their only therapy for Fabry disease. Pending positive data from this Study 012, we expect to submit a marketing application for migalastat monotherapy in Europe. We also plan to meet with the Food and Drug Administration in the fourth quarter of this year to discuss the data from both of our Phase 3 Fabry monotherapy studies, to determine the fastest U.S. registration pathway for migalastat. Together these studies represent the largest registration program ever conducted in Fabry disease. Hopefully, migalastat will become an important new medicine for the treatment of Fabry disease, where so much unmet need remains.”

Study 012 Statistical Analysis Plan:

Taking into account scientific advice from European regulatory authorities, the pre-specified co-primary outcome measures of efficacy in Study 012 are the descriptive assessments of comparability of the mean annualized change in measured (iohexol) glomerular filtration rate (mGFR) and estimated GFR (eGFR) for migalastat and ERT. Both mGFR and eGFR are considered important measures of renal function. Success on mGFR and eGFR will be measured in two ways:

  • A 50% overlap in the confidence intervals between the migalastat and ERT treatment groups; and
  • Whether the mean annualized changes for patients receiving migalastat are within 2.2 mL/min/1.73 m2/yr of patients receiving ERT.

Amicus has pre-specified that these renal function outcomes will be analyzed in patients with GLP HEK amenable mutations. Discussions with European regulators have centered on the entirety of the data to come from Study 012, considering the relatively low number of study participants due to the orphan nature of Fabry disease. In addition, in Europe the benefit/risk assessment is expected to be based on the overall data from this study and results from the entire clinical development program.

About Migalastat Monotherapy

Migalastat monotherapy is an oral small molecule pharmacological chaperone being investigated in two Phase 3 registration studies (Study 011 and Study 012) and an open-label extension study (Study 041) in Fabry patients with amenable mutations. Positive 12-month results from Study 011 were reported in the second quarter of 2014 and top-line data from Study 012 are anticipated in the third quarter of 2014.

About GLP HEK Amenable Mutations

Amenable mutations are defined as having an absolute increase of 3% of wild type alpha-Gal A enzyme activity and a relative increase of 20% when exposed to migalastat in a cell-based in vitro assay. All subjects enrolled in Study 012 had amenable mutations in the clinical trial human embryonic kidney (HEK) assay available at study initiation (“clinical trial assay”). Following the completion of enrollment, a GLP HEK assay was developed with a third party to measure the criteria for amenability with more quality control and rigor. However, approximately 10% of mutations in the HEK database switched categorization between “amenable” and “non-amenable” when moving from the clinical trial assay to the GLP HEK assay. Therefore, there were changes in categorization from amenable to non-amenable in 4 patients (2 per treatment arm) in Study 012. Based on results from mutations tested in the GLP HEK assay, Amicus continues to believe that approximately 30% to 50% of individuals with Fabry have mutations that are amenable to migalastat.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat) in combination with ERT for Pompe disease.

Forward-Looking Statements

This press release contains, and the accompanying conference call will contain, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus’ candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus’ candidate drug products and the projected cash position for the Company. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “potential,” “plan,” “targets,” “likely,” “may,” “will,” “would,” “should” and “could,” and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company’s cash position, actual results may differ based on market factors and the Company’s ability to execute its operational and budget plans. In addition, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2013. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


CONTACT: Investors/Media:
         Sara Pellegrino
         (609) 662-5044

         Dan Budwick
         (973) 271-6085
Monday, June 30th, 2014 Uncategorized Comments Off on (FOLD) Updates and Final Analysis Plan for Phase 3 Fabry Monotherapy Study 012

(TRUE) Selected to Join the Russell 2000® and Russell 3000® Indexes

SANTA MONICA, Calif., June 30, 2014  — TrueCar, Inc. (Nasdaq:TRUE), the negotiation-free car buying and selling platform, today announced that it has been added to the Russell 2000® and Russell 3000® Indexes, following Russell Investments’ annual reconstitution of its U.S. and global equity indexes on June 27, 2014.

“We are very pleased to have been selected for the Russell 2000® and Russell 3000® Indexes,” said Scott Painter, Chief Executive Officer of TrueCar. “We believe that our inclusion on the Russell indices will enable us to increase our visibility and broaden our reach among key institutional investors, as we aggressively work towards transforming the car-buying experience for consumers and dealers.”

Annual reconstitution of Russell’s U.S. indexes rebalances the 4,000 largest U.S. stocks as of the end of May each year, ranking them by total market capitalization. Membership in the Russell 3000®, which remains in place for one year, allows for automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index, as well as the appropriate growth and value style indexes. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity universe and includes approximately 2,000 of the smallest securities based on a combination of their market cap and current index membership.

Investment managers and institutional investors use Russell indexes for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $5.2 trillion in assets are currently benchmarked to them.

About TrueCar

TrueCar, Inc. (Nasdaq:TRUE) is the negotiation-free car buying and selling platform. TrueCar enables a negotiation-free car buying experience by giving buyers transparent insight into what others actually paid (price confidence), upfront pricing information (price discovery), and access to a network of trusted TrueCar Certified Dealers who provide guaranteed savings certificates and seamlessly complete the car purchase. The reality is that buying a car is painful and buyers fear they are going to overpay or be surprised with hidden fees. TrueCar’s transparent upfront pricing information makes the car buying process simple so there are no surprises and buyers never overpay. TrueCar’s mission is to make car buying simple, fair and fun. Its national network of more than 8,000 TrueCar Certified Dealers is committed to providing negotiation-free savings off MSRP for all car-buyers, including members of some of the country’s largest membership and service organizations such as AARP, American Express, AAA, and USAA. Note: Not all program features are available in all states. Go to for program details. TrueCar is headquartered in Santa Monica, Calif., with offices in Santa Barbara, Calif., San Francisco, Calif., and Austin, Texas.

         Alison Sternberg
         Vice President, Investor Relations and Administration
         O: 800.200.2000 x 8771

         Laura Bainbridge
         Addo Communications
         O: 310.829.5400

         Jenna Finn
         Kel & Partners
         O: 617.904.9393 x143
         C: 617.913.4993
Monday, June 30th, 2014 Uncategorized Comments Off on (TRUE) Selected to Join the Russell 2000® and Russell 3000® Indexes

(DRNA) Dicerna Investigational Therapy in Preclinical Model of Primary Hyperoxaluria

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced the presentation of preclinical data demonstrating the promise of DCR-PH1, the Company’s therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1), a rare inherited liver disorder that often results in progressive and severe kidney damage. The research was presented at the 11th International Primary Hyperoxaluria Workshop in Chicago by Eduardo Salido, Ph.D., Professor of Pathology at the University of La Laguna in Santa Cruz de Tenerife, Spain.

The preclinical studies showed that DCR-PH1 provides potent and long-term inhibition of HAO1, a gene implicated in the pathogenesis of PH1. In a genetically modified mouse model of PH1, researchers reported a 97 percent reduction of the HAO1 transcript in the liver after a single dose of DCR-PH1 and a significant reduction in urinary oxalate levels, a key marker of the disease. In mice treated with DCR-PH1, urinary oxalate levels returned to near baseline levels, similar to normal mice.

“Physicians, patients and families managing PH1 currently have limited to no effective treatment for this severe and progressive disease,” noted Craig B. Langman, M.D., chair of the workshop and the Isaac A. Abt, M.D., Professor of Kidney Diseases, and Head, Kidney Diseases, at the Ann & Robert H. Lurie Children’s Hospital of Chicago and the Feinberg School of Medicine of Northwestern University. “Based on these encouraging preclinical data, we look forward to beginning clinical trials to determine the potential role of DCR-PH1 in the treatment of PH1.”

PH1 occurs when a liver enzyme called AGT does not function properly due to a genetic defect, inducing the liver to over-produce a metabolite called oxalate. While oxalate has no clinical effect in a healthy population, it is concentrated in the urine by the kidneys of patients with PH1, forming calcium oxalate crystals that can lead to chronic and painful cases of kidney stones, scarring of the kidney and end-stage renal disease.

DCR-PH1 is engineered to address the pathology of PH1 by targeting and destroying the messenger RNA (mRNA) produced by HAO1, a gene that encodes glycolate oxidase, a protein involved in producing oxalate. By reducing oxalate production, this approach is designed to prevent the complications of PH1.

“Our preclinical studies indicate that inhibition of the gene HAO1 prevents expression of glycolate oxidase, as expected, and may therefore reduce significantly the abnormally high oxalate production found in patients with PH1,” commented Dr. Salido. “By blocking production of glycolate oxidase in the liver, DCR-PH1 may prevent the severe kidney damage that is characteristic of PH1.”

“Dr. Salido’s data lend further support to the use of the Dicer Substrate RNAi technology platform, which we believe improves upon existing RNAi technologies in the treatment of rare, genetically defined diseases involving the liver,” stated Pankaj Bhargava, M.D., Chief Medical Officer of Dicerna. “We look forward to initiating clinical trials of DCR-PH1 to validate these preclinical findings in humans.”

About PH1

PH1 is a rare, serious, inherited liver disorder that often results in oxalosis, a rare metabolic disorder that causes severe damage to the kidneys. The disease can be fatal unless the patient undergoes a liver-kidney transplant, a major surgical procedure that is often difficult to perform due to the lack of donors and the threat of organ rejection. Even in the event of a successful transplant, the patient must live the rest of his or her life on immunosuppressant drugs, which have substantial associated risks.

PH1 is characterized by a genetic deficiency of the liver enzyme AGT (alanine:glyoxalate aminotransferase), which is encoded by the AGXT gene. AGT deficiency induces overproduction of oxalate by the liver, resulting in the formation of crystals of calcium oxalate in the kidneys. Oxalate crystal formation often leads to chronic and painful cases of kidney stones and subsequent fibrosis (scarring), which is known as nephrocalcinosis. Many patients progress to end-stage renal disease (ESRD) and require dialysis or transplant. Aside from having to endure frequent dialysis, PH1 patients with ESRD may experience a build-up of oxalate in the bone, skin, heart and retina, with concomitant debilitating complications. Currently, aside from dual liver and kidney transplant, there are no highly effective therapeutic options for most patients with PH1. While the true prevalence of primary hyperoxaluria is unknown, the estimated prevalence of PH1 is 1 to 3 cases per 1 million people.1 Fifty percent of patients with PH1 reach ESRD by their late 30s.2

About EnCoreTM Technology

Dicerna uses EnCore lipid nanoparticles, the company’s proprietary delivery system, to deliver the Dicer Substrate RNA (DsiRNA) molecule DCR-PH1 to liver tissues. Once in the liver, the DsiRNA leads to the specific destruction of the gene transcript that encodes the enzyme glycolate oxidase, which is responsible for the pathologic accumulation of oxalate in PH1. This process is highly specific for the targeted gene.

About RNAi

RNAi is a highly potent and specific mechanism for regulating the activity of a targeted gene. In this biological process, certain double-stranded RNA molecules known as short interfering RNAs (siRNAs) bind to complementary messenger RNAs (mRNAs) and recruit proteins that break the chemical bonds that hold mRNAs together, preventing the mRNAs from transmitting their protein-building instructions.

Dicerna’s proprietary RNAi molecules are known as Dicer Substrates, or DsiRNAs, so called because they are processed by the Dicer enzyme, which is the initiation point for RNAi in the human cell cytoplasm. Dicerna’s discovery approach is believed to maximize RNAi potency because the DsiRNAs are structured to be ideal for processing by Dicer. Dicer processing enables the preferential use of the correct RNA strand of the DsiRNA, which may increase the efficacy of the RNAi mechanism, as well as the potency of the DsiRNA molecules relative to other molecules used to induce RNAi.

About Dicerna Pharmaceuticals, Inc.

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have historically been difficult to inhibit using conventional approaches, but where connections between targets and diseases are well understood and documented. The Company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.

Cautionary Contact on Forward-looking Statements

This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those relating to our preclinical research and other risks identified under the heading “Risk Factors” included in our Form 10-Q dated May 14, 2014, and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna’s current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.


1 Cochat, P, Rumsby, G. Primary hyperoxaluria. The New England Journal of Medicine 2013; 369(7): 649-658.

2 Rare Kidney Stone Consortium. Primary Hyperoxaluria. 2010. Available at: Accessed June 25, 2014.

Monday, June 30th, 2014 Uncategorized Comments Off on (DRNA) Dicerna Investigational Therapy in Preclinical Model of Primary Hyperoxaluria

(REFR) SPD-Smartglass Panels Are Now Protecting Light-Sensitive Artifacts at Smithsonian

WASHINGTON, DC–(Jun 27, 2014) –  Research Frontiers’ (NASDAQ: REFR) VariGuard business unit announced today that the Smithsonian’s National Postal Museum will use VariGuard’s panels based on SPD-SmartGlass technology at the “Behind the Badge” exhibition opening June 27 in Washington, DC. These panels protect light-sensitive artwork and documents from damage from visible light by electronically changing its transparency from dark to clear instantly at the push of a button or automatically.

This exhibit will showcase the work of one of the nation’s oldest federal law enforcement agencies and examine the wide range of work done by its inspectors. VariGuard panels are featured in several display cases that showcase historic light-sensitive artifacts.

Seth Van Voorhees, President of VariGuard, commented: “VariGuard display panels offer the best protection for light sensitive artifacts in the industry. Awareness of the protective benefits of VariGuard panels is growing in the museum community and with private collectors, permitting artifacts to be shown without fear of damage from visible light.”

VariGuard uses patented SPD-SmartGlass technology that allows visible light to reach an object only when it is desired; at all other times VariGuard display panels are in their
light-blocking dark state protecting the artifact. As a result, VariGuard panels provide a better viewing experience (by allowing substantially higher gallery illumination levels), while simultaneously reducing damaging visible light-exposure to artifacts by up to

More information about VariGuard panels for display cases, wall cases and frames is available at

About the Smithsonian National Postal Museum

The National Postal Museum is devoted to presenting the colorful and engaging history of the nation’s mail service and showcasing one of the largest and most comprehensive collections of stamps and philatelic material in the world. It is located at 2 Massachusetts Avenue N.E., Washington, D.C., across from Union Station. For more information about the Smithsonian, call (202) 633-1000 or visit the museum. For more information about the Smithsonian’s “Behind the Badge” Exhibition, please visit

About VariGuard and Research Frontiers Inc.

VariGuard SmartGlass™ and SmartPlastic™ are the first and only display panels that offer a wide range of visible light transmission, instant switching between dark and clear states, and >99% UV-blocking at all times. Based on patented SPD light-control technology developed by Research Frontiers, VariGuard display panels optimally protect artifacts by limiting their light-exposure only to those times when people are viewing them.

Research Frontiers Incorporated, the developer of SPD-SmartGlass electronic-tint technology which allows users to instantly, precisely and uniformly control the amount of light coming through glass or plastic, either manually with the touch of a button or automatically. Research Frontiers has built an infrastructure of over 40 licensed companies that collectively are capable of serving the growing global demand for smart glass products in automobiles, homes, buildings, museums, aircraft and boats. For more information, please visit our website at, or Facebook, Twitter, LinkedIn, YouTube and Instagram.

Note: From time to time Research Frontiers may issue forward-looking statements which involve risks and uncertainties. This press release contains forward-looking statements. Actual results could differ and are not guaranteed. Any forward-looking statements should be considered accordingly. “SPD-Smart”, “SPD-SmartGlass” “VariGuard”, “VariGuard SmartGlass” and “VariGuard SmartPlastic” are trademarks of Research Frontiers and its subsidiary VariGuard.

Friday, June 27th, 2014 Uncategorized Comments Off on (REFR) SPD-Smartglass Panels Are Now Protecting Light-Sensitive Artifacts at Smithsonian

(PATK) Completes Acquisition of Foremost Fabricators, LLC

ELKHART, Ind., June 27, 2014  — Patrick Industries, Inc. (NASDAQ: PATK) (“Patrick” or the “Company”) announced today that it has completed the acquisition of the business and certain assets of Goshen, Indiana-based Foremost Fabricators, LLC (“Foremost”).    Foremost is a fabricator and distributor of fabricated aluminum products, fiber reinforced polyester sheet and coil, and custom laminated products primarily used in the recreational vehicle (“RV”) market.  The Company estimates Foremost’s 2014 annual revenues to be approximately $75 million and expects the acquisition to be immediately accretive to 2014 net income per share.

“The acquisition of Foremost, which is recognized as the industry leader in the laminated and fabricated roll formed aluminum product lines primarily used for exterior sidewalls in the RV market, will help us to bring new value added product lines to our customer base,” said Todd Cleveland, President and Chief Executive Officer of Patrick.  “Consistent with our strategic growth initiatives in conjunction with our capital allocation and acquisition strategies, we are excited to have the opportunity to allow the entrepreneurial spirit of this highly respected organization to continue to thrive while supporting the business with the financial and operational foundation that will enable it to align with our Company mission of bringing the highest quality products, service and value to our customers.  In addition, the acquisition of Foremost will allow Patrick to further expand its presence in the RV market and increase our product offerings, market share, and per unit content.”

Bud Stout, Chief Executive Officer and Founder of Foremost, said, “The exceptional team at Foremost is excited and energized to join the Patrick organization whose core values, competencies, relationships, and customer first approach mirror those that we have worked hard to build and maintain on a consistent high quality basis.  While I plan to begin the next chapter of my life following the union with Patrick, the other shareholders and team members are planning to continue to drive the business model, and I am confident that Foremost has aligned with the right business partner to grow the Foremost brand and further embed the philosophies that have allowed us to be successful.  Patrick is a natural fit for our operation, and the additional manufacturing and distribution expertise and financial resources that they bring can help propel Foremost to the next level.”

The net purchase price for Foremost of approximately $45 million was funded under the Company’s newly expanded credit facility (see discussion  below) and includes the acquisition of accounts receivable, inventory, prepaid expenses, and machinery and equipment.  Patrick will continue to operate the business on a stand-alone basis under the Foremost brand name in its existing facilities.

“Foremost’s excellent reputation in the industry, which has been built upon years of providing high quality products and service and industry leading expertise to its customer base, will allow us to establish a strong presence in the aluminum products market while providing opportunities to expand our array of products and services to the RV market through existing sales channels and into new markets,” said Mr. Cleveland.  “We are honored to have the opportunity to partner with the Foremost team, and motivated by the challenge to uphold the highly respected legacy that they have created in the industry.  Additionally, we are excited about bringing our two companies together to maximize resources, synergies and buying power, strengthen customer relationships through value added innovation and intuitive designs, bring a broad spectrum of products and price points to our customer base, and improve overall profitability through the continued execution of our strategic plan.”

Credit Facility Expansion

In conjunction with the Foremost acquisition, the Company entered into a fourth amendment, dated June 26, 2014, to its current five-year $80 million revolving secured senior credit facility that was established on October 24, 2012 (the “2012 Credit Facility”) with Wells Fargo Bank, National Association as the agent and lender (“Wells Fargo”), and Fifth-Third Bank (“Fifth-Third”), as participant (collectively, the “Lenders”).  The fourth amendment expands the 2012 Credit Facility to $125 million and replenishes the capacity under the credit agreement to continue to make permitted acquisitions.

“We are excited to have expanded the size of our credit facility, which provides increased availability, as well as a strong financing platform to support the Company’s strategic initiatives, our organic and acquisition-related growth needs, and our ongoing working capital requirements.  In addition, we look forward to our continued partnership with Wells Fargo and Fifth-Third as we strive to continue to achieve the deliverables under our strategic plan,” stated Mr. Cleveland.

About Patrick Industries

Patrick Industries, Inc. ( is a major manufacturer of component products and distributor of building products serving the recreational vehicle, manufactured housing, kitchen cabinet, office and household furniture, fixtures and commercial furnishings, marine, and other industrial markets and operates coast-to-coast through locations in 10 states.  Patrick’s major manufactured products include decorative vinyl and paper laminated panels, countertops, wrapped profile mouldings, slide out trim and fascia, cabinet doors and components, hardwood furniture, fiberglass bath fixtures, interior passage doors, exterior graphics and RV painting, and slotwall panels and components.  The Company also distributes drywall and drywall finishing products, electronics, wiring, electrical and plumbing products, cement siding, interior passage doors, roofing products, laminate and ceramic flooring, shower doors, furniture, fireplaces and surrounds, interior and exterior lighting products, and other miscellaneous products.

Forward-Looking Statements 

This press release contains certain statements related to future results, or states our intentions, beliefs and expectations or predictions for the future, which are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from either historical or anticipated results depending on a variety of factors.  Potential factors that could impact results include: the impact of any economic downturns especially in the residential housing market, pricing pressures due to competition, costs and availability of raw materials, availability of commercial credit, availability of retail and wholesale financing for residential and manufactured homes, availability and costs of labor, inventory levels of retailers and manufacturers, levels of repossessed residential and manufactured homes, the financial condition of our customers, retention and concentration of significant customers, the ability to generate cash flow or obtain financing to fund growth, future growth rates in the Company’s core businesses, the ability to effectively manage the costs and the implementation of the new enterprise resource management system, the successful integration of acquisitions, stock price fluctuations, interest rates, oil and gasoline prices, the outcome of litigation, adverse weather conditions impacting retail sales, and our ability to remain in compliance with our credit agreement covenants.  In addition, national and regional economic conditions and consumer confidence may affect the retail sale of recreational vehicles and residential and manufactured homes.  The Company does not undertake to update forward-looking statements, except as required by law.  Further information regarding these and other risks, uncertainties and factors is contained in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, and in the Company’s Form 10-Qs for subsequent quarterly periods, which are filed with the Securities and Exchange Commission (“SEC”) and are available on the SEC’s website at

Friday, June 27th, 2014 Uncategorized Comments Off on (PATK) Completes Acquisition of Foremost Fabricators, LLC

(PLNR) Most Innovative Video Display and Best of Show at InfoComm 2014

Planar Systems, Inc. (NASDAQ: PLNR), a global leader in display and digital signage technology, announced that two of its key product offerings have been recognized with top awards from AV and digital signage experts at Systems Contractor News and Digital Signage magazine.

The Planar® UltraRes™ Series 84-inch 4K LCD display was voted Most Innovative Video Display” among LCD, Plasma, OLED and LED panels by readers of Systems Contractor News magazine. Likewise, the Clarity™ Matrix LCD Video Wall System with G2 Architecture was named a Digital SignageInfoComm 2014 Best of Show” award winner. Both awards were announced at InfoComm 2014 in Las Vegas, where both the Planar UltraRes Series and the Clarity Matrix LCD Video Wall were on display.

“We are so appreciative to the readers of Systems Contractor News and Digital Signage for these meaningful awards,” said Jennifer Davis, vice president of marketing at Planar Systems. “It’s an honor to be recognized for 4K display leadership with the Planar UltraRes Series and for our pioneering efforts in video wall technology with Clarity Matrix.”

Introduced in February 2013, Planar UltraRes Series ultra HD displays are designed for resolution-rich commercial applications including energy, geospatial, engineering and design, architecture, aerospace, control room, collaborative conference room, medical imaging, science and digital signage, among others. Whether it’s making a multi-million dollar energy exploration decision, quickly re-routing electricity to prevent an outage or producing stunning close-up video for a retail store, Planar UltraRes Series 4K displays help businesses get the most impact from ultra-high resolution information.

The next-generation Clarity Matrix LCD Video Wall System with G2 Architecture is an immersive, flexible video wall that combines the industry’s thinnest profile ultra-narrow bezel LED LCD displays with best-in-class design, installation and service. Clarity Matrix with G2 Architecture sets a new benchmark with outstanding image quality, simplified installation and maintenance, and 24×7 mission-critical reliability.

Both the Planar UltraRes Series and the Clarity Matrix LCD Video Wall with G2 Architecture are available through Planar’s global network of authorized resellers. For more information, please visit or

About Planar

Planar Systems Inc. (NASDAQ: PLNR) is a global leader in display and digital signage technology, providing premier solutions for the world’s most demanding environments. Retailers, educational institutions, government agencies, businesses, utilities and energy firms, and home theater enthusiasts all depend on Planar to provide superior performance when image experience is of the highest importance. Planar video walls, large format LCD displays, interactive touch screen monitors and many other solutions are used by the world’s leading organizations in applications ranging from digital signage to simulation and from interactive kiosks to large-scale data visualization. Founded in 1983, Planar is headquartered in Oregon, USA, with offices, manufacturing partners and customers worldwide. For more information, visit

Friday, June 27th, 2014 Uncategorized Comments Off on (PLNR) Most Innovative Video Display and Best of Show at InfoComm 2014

(ALDR) Added to Russell 3000® Index

BOTHELL, Wash., June 27, 2014  — Alder BioPharmaceuticals, Inc., (“Alder”) (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced that Alder will be added to the Russell 3000® Index at the close of the market today, Friday, June 27, 2014 when Russell Investments reconstitutes its set of U.S. and global equity indexes.

Annual reconstitution of Russell’s U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. The Russell 3000 measures the performance of the largest 3,000 U.S. companies representing approximately 98% of the investable U.S. equity market. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. The Russell 3000 also serves as the U.S. component to the Russell Global Index. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.

“We are very pleased to be included in the Russell 3000 Index,” commented Randall C. Schatzman, Ph.D., President and Chief Executive Officer of Alder. “We believe that Alder’s inclusion in the Russell Indexes so shortly after our IPO will further bolster our visibility and reach in the investment community as we advance our pipeline toward several value inflection points over the next 12 months.”

Russell Indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. Approximately $5.2 trillion in assets are benchmarked to the Russell Indexes.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s wholly-owned therapeutic program, an investigational monoclonal antibody for migraine, ALD403, inhibits a well-validated molecule shown to trigger migraine attacks, calcitonin gene-related peptide (CGRP), and is now undergoing clinical testing. Alder plans to advance ALD403 into a Phase 2b trial in the second half of 2014. Clazakizumab, previously known as ALD518, is Alder’s investigational monoclonal antibody to the pro-inflammatory cytokine IL-6. Bristol-Myers Squibb is investigating Clazakizumab (as BMS-945429) in a Phase 2b clinical study in rheumatoid arthritis and other autoimmune indications based on a 2009 partnership. Alder’s management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics and enabling partners through the out-licensing of its technologies. For more information, please visit

Forward Looking Statements

This press release contains forward-looking statements. All forward-looking statements included in this press release are based on our management’s beliefs and assumptions and on information currently available to our management, and we assume no obligation to update any such forward-looking statements. Any or all of our forward-looking statements in this document may turn out to be wrong and actual events or results may differ materially. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and other factors. In evaluating these statements, you should specifically consider various factors, including the risks outlined under the caption “Risk Factors” set forth in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 filed with the Securities and Exchange Commission (SEC) and other reports and filings we will make with the SEC from time to time. We caution investors that our business and financial performance are subject to substantial risks and uncertainties.

CONTACT: Media Contacts:
         David Schull or Andrea Flynn, Ph.D.
         Russo Partners
         (212) 845-4271
         (646) 942-5631

         Investor Relations Contact:
         Sarah McCabe
         Stern Investor Relations, Inc.
         (212) 362-1200
Friday, June 27th, 2014 Uncategorized Comments Off on (ALDR) Added to Russell 3000® Index

(TECU) Makes Board and Executive Leadership Changes

ANN ARBOR, Mich., June 27, 2014  — Harold Karp has been named interim President and Chief Executive Officer of Tecumseh Products Company (Nasdaq:TECU) following the resignation of James Connor. The Tecumseh Board of Directors also approved the appointment of Gary Cowger as Chairman.

“Tecumseh will immediately benefit from Harold’s strong leadership skills and global manufacturing expertise which he has developed over the years,” said Cowger. “Harold has a wealth of experience leading worldwide manufacturing businesses, enhancing their quality and productivity while stimulating innovation and growth.”

For 18 years, Karp was employed by The Alpine Group, Inc. or one of its portfolio companies, serving in various senior operating and executive positions. The Alpine Group is an investment firm that operated and actively managed companies in the refrigeration, specialty materials, coatings, wire and cable products and electronic components sectors.  Karp served as President and Chief Operating Officer from February 2007 to December 2013 of Wolverine Tube, Inc., which manufactured custom-engineered products providing thermal management solutions to the HVAC, refrigeration, appliance, electronic cooling and petrochemical markets. Karp has served on the Tecumseh Board of Directors since January 2014.

“I am excited to be named the CEO of Tecumseh,” said Karp. “I believe in the strength of the Tecumseh brand and in its global distribution network, and I am committed to enhancing both through innovative product development. We are going to renew our focus on customer satisfaction and product quality with a sense of urgency to reaffirm Tecumseh as a global leader in our industry. With our new leaders in engineering, operations and restructuring, I am confident that we are well-prepared to meet the challenges and opportunities as they are presented to Tecumseh.”

Cowger’s appointment as Chairman of the Board, together with the recent additions of four Directors, provide a broad range of public company, operational, financial and industry experience. A recent successful recapitalization, aligning voting control with share ownership, is an example of the Board’s commitment to moving Tecumseh forward.

Tecumseh also announced that it is engaging in an executive search for a permanent President and CEO, with the anticipation that Karp will be a strong candidate for that position.

Tecumseh Products Company is a global manufacturer of hermetically sealed compressors for residential and specialty air conditioning, household refrigerators and freezers, and commercial refrigeration applications, including air conditioning and refrigeration compressors, as well as condensing units, heat pumps and complete refrigeration systems.  Press releases and other investor information can be accessed via the Investor Relations section of Tecumseh Products Company’s website at

Company Contact:
Roger Jackson ▪ 734-585-9482 ▪

Friday, June 27th, 2014 Uncategorized Comments Off on (TECU) Makes Board and Executive Leadership Changes

(AMED) Previews Second Quarter 2014 Results

BATON ROUGE, La., June 27, 2014  — Amedisys, Inc. (Nasdaq:AMED), one of America’s leading home health and hospice care companies, today announced its expectations for certain financial results for the second quarter ending June 30, 2014. Amedisys anticipates second quarter revenue in the range of $300-$305 million, and adjusted earnings per share (“EPS”) from continuing operations of between $0.15 and $0.20. These results are subject to completion of the quarter, as well as the Company’s quarterly financial and accounting procedures, and the Company’s actual results could vary from these estimates.

The Company previously announced plans to close or consolidate care centers and right-size general and administrative expenses. As a result of these initiatives, the Company has been able to improve gross margins and reduce direct and general and administrative costs, favorably impacting second quarter results.

While these results represent a significant improvement from the first quarter, we remain cautious on our full-year outlook due to the seasonality of the business and the early-stage nature of some of the performance initiatives undertaken thus far in 2014.

Amedisys will discuss these results in more detail on its second quarter earnings conference call scheduled for Wednesday, July 30, 2014 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time).

About Amedisys:

Amedisys, Inc. (Nasdaq:AMED) is a leading healthcare at home company delivering personalized home health and hospice care to more than 360,000 patients each year. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based recovery and rehabilitation after an operation or injury, care focused on empowering them to manage a chronic disease, palliative care for those with a terminal illness, or hospice care at the end of life. Amedisys also has the industry’s first-ever nationwide Care Transitions program, designed to reduce unnecessary hospital readmissions through patient and caregiver health coaching and care coordination, which starts in the hospital and continues throughout completion of the patient’s home health plan of care. For more information about the Company, please visit:

Forward-Looking Statements

When included in this press release, words like “believes,” “belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, changes in or our failure to comply with existing Federal and State laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the home health industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in payments and covered services due to the economic downturn and deficit spending by Federal and State governments, future cost containment initiatives undertaken by third-party payors, our access to financing due to the volatility and disruption of the capital and credit markets, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate and manage our information systems, our ability to fund required settlement payments in the manner agreed upon in our settlement agreement to resolve both the U.S. Department of Justice investigation and the Stark Law Self-Referral matter, our ability to comply with requirements stipulated in our corporate integrity agreement and change in law or developments with respect to any litigation or investigations relating to the Company, including the SEC investigation, the OIG Self-Disclosure issues and various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

Non-GAAP Financial Measures

This press release includes the following non-GAAP financial measure as defined under SEC rules: adjusted earnings per share from continuing operations, defined as net income (loss) from continuing operations attributable to Amedisys, Inc. common stockholders per diluted share plus the earnings per share effect of certain items. Management believes that adjusted earnings per share from continuing operations is a useful gauge of our performance and is a common measure used in our industry to assess relative financial performance among companies.

CONTACT: Amedisys, Inc.
         Director, Treasury/Finance
         David Castille
Friday, June 27th, 2014 Uncategorized Comments Off on (AMED) Previews Second Quarter 2014 Results

(ROYL) 325 Million Barrel Oil Target

NSAI Concludes Prospective Resource Review

SAN DIEGO, June 26, 2014  — Royale Energy, Inc. (Nasdaq:ROYL) today announced the results of an independent review of the prospective resource potential of two recently identified North Slope Alaska drilling targets. Global independent expert, Netherland Sewell and Associates (NSAI) reviewed geological and geophysical data including the recently acquired 3D seismic survey, and concluded that the targets contain 17.8 to 325.3 Million barrels of oil in place. Present expectation of recovery ranges from 14% to 42% of oil in place.

The prospects assessed are the largest two features identified from the recently acquired Big Bend seismic survey, and include contributions from both the Brookian and Alpine reservoirs on lands currently leased from the State of Alaska. The company has applied for permits to drill two locations during the upcoming winter drilling season utilizing the Kuukpic #5 drilling rig, which is currently under contract. In addition to targeting these conventional reservoirs, the wells will be designed to evaluate the unconventional/shale potential. The resource potential of the HRZ, Lower Kingak and Shublik shales were previously evaluated by NSAI, and determined to have the potential of 661,000 barrels of oil per well.

Torey Marshall, Managing Director of Rampart Energy Ltd said, “We are very pleased with NSAI’s assessment of the Western Block, which validates the Joint Venture’s opinion of the block’s potential for hosting significant oil discoveries.”

Following the submittal of permits to drill two wells this season, additional prospects are expected to be identified as the company continues to analyze the seismic data volumes over the next several months.

Undiscovered STOOIP (MMBBL) Undiscovered OGIP (BCF)
Low Best High Low Best High
Brookian 2.896 21.448 135.701 1.823 14.070 90.683
Alpine 14.889 56.050 189.647 9.291 37.122 127.949
Combined Targets 17.785 77.497 325.349 11.113 51.192 218.632

Forward Looking Statements

In addition to historical information contained herein, this news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, subject to various risks and uncertainties that could cause the company’s actual results to differ materially from those in the “forward-looking” statements. While the company believes its forward looking statements are based upon reasonable assumptions, there are factors that are difficult to predict and that are influenced by economic and other conditions beyond the company’s control. Investors are directed to consider such risks and other uncertainties discussed in documents filed by the company with the Securities and Exchange Commission.

CONTACT: Royale Energy, Inc.
         Chanda Idano, Director of Marketing & PR
Thursday, June 26th, 2014 Uncategorized Comments Off on (ROYL) 325 Million Barrel Oil Target

(LOCM) Havvit™ Shopping App Secures Industry Recognition

Local Corporation (NASDAQ: LOCM), a leading local advertising technology company, announced that its Havvit™ shopping app has received award recognition from three major industry award organizations.

Powered by the company’s patented Krillion® local shopping platform, Havvit was selected by The Academy of Interactive and Visual Arts to receive a 2014 Communicator Award of Distinction; was a finalist for MediaPost’s 2014 Appy Awards; and is an official Honoree in The 18th Annual Webby Awards in the Shopping (Handheld Devices) category presented by the International Academy of Digital Arts and Sciences.

“Being recognized by three esteemed industry organizations is testament to Havvit’s capabilities and its ability to influence on-the-go consumers throughout the shopping experience from Discovery to Decision™,” said Fred Thiel, Local Corporation chairman and chief executive officer. “We are honored to receive this prestigious recognition for Havvit and Krillion, and look forward to continuing to provide innovative shopping solutions and technology.”

Local Corporation’s Havvit app, one of the first local shopping apps of its kind, delivers a highly personalized and intuitive shopping experience. Havvit supports mobile consumers, allowing them to track savings, compare prices and find products nearby, all from their pre-selected favorite stores and brands.

The latest version of Havvit incorporates Krillion’s StockCheck™ technology, which provides real-time inventory availability, and informs shoppers if the product they want is in stock and available at nearby stores. It also includes Krillion’s smart price comparison feature that alerts shoppers if the product they are looking for is available at a lower price from another retailer nearby. Download the free, iOS® 7-compatible Havvit app from iTunes® (

The Communicator Awards is an annual competition honoring the best in advertising, corporate communications, public relations and identity work for print, video, interactive and audio. With over 6,000 entries received from across the US and around the world, the Communicator Awards is the largest and most competitive awards program honoring creative excellence for communications professionals. The Communicator Awards are judged and overseen by the Academy of Interactive and Visual Arts (AIVA), a 600+ member organization of leading professionals from various disciplines of the visual arts dedicated to embracing progress and the evolving nature of traditional and interactive media.

The Appys honor extraordinary applications on all platforms: mobile, social and web-based. They are unbiased to an app’s format, platform or device; instead they focus on the best apps in a diverse range of categories, from Games and News, to Health and Fitness, Social Networking, Photography and many others.

The Webby Awards is the leading international award honoring excellence on the Internet. Established in 1996, The Webby Awards is presented by the International Academy of Digital Arts and Sciences (IADAS) — a 1,000+ member judging body is comprised of leading web experts, business figures, luminaries, visionaries and creative celebrities, and other Internet professionals. The Webby Awards received nearly 12,000 entries from all 50 states and over 60 countries worldwide this year.

About Local Corporation

Local Corporation (NASDAQ:LOCM) is a leading local advertising technology company that connects millions of online and mobile consumers with businesses and products through a variety of innovative digital advertising solutions. The company’s patented Krillion® local shopping platform aggregates, localizes and distributes dynamic, national and regional retail shopping content, from approximately 120,000 store locations, representing nearly 3 million localized products. For more information, visit: or To download the company’s iOS® 7-compatible Havvit™ shopping app, go to: iTunes® (

Forward-Looking Statements

This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Words or expressions such as “anticipate,” “plan,” “will,” “intend,” “believe” or “expect” or variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Key risks are described in the filings we make with the U.S. Securities and Exchange Commission. The forward-looking statements in this release speak only as of the date they are made. We undertake no obligation to revise or update publicly any forward-looking statement for any reason. Unless otherwise stated, all site traffic and usage statistics are from third-party service providers engaged by the company. Traffic and our monetization of that traffic combine to determine our revenues for any given period. Our traffic volume alone for a period should not be viewed as demonstrative of our financial results for such period.

Thursday, June 26th, 2014 Uncategorized Comments Off on (LOCM) Havvit™ Shopping App Secures Industry Recognition

(FEIM) Announces New Satellite Contract

MITCHEL FIELD, N.Y., June 26, 2014  — Frequency Electronics, Inc. (Nasdaq:FEIM) announced it has been awarded a new satellite contract anticipated to exceed $11 million. The contract calls for Frequency to design and develop a payload master timing and frequency generator system for U.S. Government end-use. Work on this cost-plus contract is expected to be completed within eighteen months followed by additional orders for flight systems. Frequency was selected for this important contract award based on its state-of-the-art, low phase noise/short-term stability time and frequency technology.

About Frequency Electronics

Frequency Electronics, Inc. is a world leader in the design, development and manufacture of high precision timing, frequency control and synchronization products for space and terrestrial applications. Frequency’s products are used in commercial, government and military systems, including satellite payloads, C4ISR markets, missiles, UAVs, aircraft, GPS, secure radios, energy exploration and wireline and wireless communication networks. Frequency has received over 100 awards of excellence for achievements in providing high performance electronic assemblies for over 150 space and DOD programs. The Company invests significant resources in research and development and strategic acquisitions world-wide to expand its capabilities and markets.

Frequency’s Mission Statement: “Our mission is to provide precision time and low phase noise frequency generation systems from 1 Hz to 42 GHz, for space and other challenging environments.”

Subsidiaries and Affiliates: Gillam-FEI provides expertise in wireline network synchronization and SCADA; FEI-Zyfer provides GPS and secure timing (“SAASM”) capabilities for critical military and commercial applications; FEI-Asia provides cost effective manufacturing and distribution capabilities in a high growth market; FEI-Elcom Tech provides added resources for state-of-the-art RF microwave products. Frequency’s Morion affiliate supplies high-quality, cost effective quartz oscillators and components. Additional information is available on the Company’s website:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

The Statements in this press release regarding the future constitute “forward-looking” statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, inability to integrate operations and personnel, actions by significant customers or competitors, general domestic and international economic conditions, consumer spending trends, reliance on key customers, continued acceptance of the Company’s products in the marketplace, competitive factors, new products and technological changes, product prices and raw material costs, dependence upon third-party vendors, competitive developments, changes in manufacturing and transportation costs, the availability of capital, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

CONTACT: Alan Miller, CFO, or General Joseph P. Franklin, Chairman:
         TELEPHONE: (516) 794-4500
Thursday, June 26th, 2014 Uncategorized Comments Off on (FEIM) Announces New Satellite Contract

(CBMG) Completes Enrollment in Phase IIb Clinical Trial for ReJoin

PALO ALTO, Calif., June 26, 2014  — Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the “Company”) today announced that it has completed the patient enrollment required for its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell (haMPC)-based therapy ReJoinTM for Knee Osteoarthritis (KOA).

“We are pleased to reach this Company milestone and exceed enrollment of the forty-eight patients required for our Phase IIb clinical trial for Knee Osteoarthritis,” said Dr. Cheng Xiang (Chase) Dai, VP and GM of Autologous Products Business Unit.

The Phase I/IIa clinical trial for this therapy was completed in Q4 2013, with the six-month follow-up data analysis concluding that ReJoinTM cell therapy for KOA patients is safe and revealing an increase in cartilage volume as early as three months after the therapy. (click here to view detailed six-month data)

About the Clinical Trial

The Phase IIb clinical research trial for KOA, registered with the U.S. National Institutes of Health (NIH) under the number NCT02162693 (click here to view), is led by Shanghai Renji Hospital, one of the largest teaching hospitals in China. The multi-center study has enrolled 53 patients to participate in a randomized, single blind trial.

The primary endpoints for this trial are knee-related pain, stiffness and function as measured using the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index questionnaire. The secondary endpoints are cartilage repair at six months by assessment of changes of the knee joint cartilage’s volume measured with quantitative magnetic resonance imaging (MRI), in addition to NRS-11, SF-36 and KSCRS scores, and the recording of any moderate to serious adverse events.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit:

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly
         Director of Corporate Communications, CBMG
         +1 650 566-5064

         Vivian Chen
         Managing Director Investor Relations, Grayling
         +1 646 284-9427
Thursday, June 26th, 2014 Uncategorized Comments Off on (CBMG) Completes Enrollment in Phase IIb Clinical Trial for ReJoin

(QLTI) to Merge with (AUXL)

CHESTERBROOK, Pa. and VANCOUVER, Canada, June 26, 2014  — Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, and QLT Inc. (NASDAQ: QLTI) (TSX: QLT), a Canadian-based biotechnology company focused on developing innovative orphan ophthalmology products, today announced that they have entered into a definitive agreement under which Auxilium plans to merge with QLT. The transaction is expected to drive shareholder value creation by accelerating Auxilium’s ongoing transformation into a leading diversified North American specialty biopharmaceutical company. As a result of the merger, Auxilium expects to have an expanded corporate platform that includes focused investments in research and development and the continued pursuit of new products and M&A due to cost and tax synergies. The companies also intend to continue to pursue a potential partnering agreement for QLT’s promising late-stage retinoid program.

Under the terms of the agreement, a wholly-owned subsidiary of QLT will be merged with and into Auxilium. QLT will remain incorporated in British Columbia, Canada, and will be renamed “New Auxilium.” Current shareholders of Auxilium will receive 3.1359 QLT shares for each Auxilium share, subject to certain adjustments. For QLT shareholders, the transaction represents a 25% premium based on a calculation of the closing NASDAQ stock prices of Auxilium and QLT on June 25, 2014, the last trading day prior to the announcement of the merger. When completed, Auxilium shareholders will own approximately 76% of the combined entity on a fully diluted basis, and current QLT shareholders will own approximately 24%, subject to certain adjustments.

Adrian Adams, Chief Executive Officer and President of Auxilium, stated, “Building on Auxilium’s strong foundation and commercial expertise, the merger with QLT represents a unique opportunity to accelerate our desired strategic transformation into a leading, diversified North American specialty biopharmaceutical company. We are creating what we believe is a more competitive and efficient platform to capitalize on greater market opportunities and position Auxilium to deliver meaningful value for shareholders while enhancing our ability to invest in and offer innovative products that make a difference in the lives of underserved patients.”

“We believe that this is an excellent transaction for QLT shareholders and provides them with the opportunity to benefit from the potential upside of the combined company,” said Jason Aryeh, Chairman of QLT. “We believe that Adrian Adams and the Auxilium team have proven their ability to execute and deliver on a strategy for providing quality specialty biopharmaceutical products to fill significant unmet medical needs around the world. I am confident that under their leadership, and with the advantages presented by our combined organization, this transaction will leave the merged company well-positioned to achieve sustained growth.”

The combined organization will be led by Auxilium’s current leadership team and will maintain Auxilium’s current offices in Chesterbrook, Pennsylvania. All current Auxilium directors are expected to join the merged company’s board, joined by two current QLT directors. Auxilium does not expect any material changes to its current U.S. operations or employment as a result of this transaction, and expects to grow its presence in both the U.S. and Canada. Shares of the combined company are expected to trade on NASDAQ and QLT is expected to be delisted from the Toronto Stock Exchange.

Mr. Adams continued, “We believe this transaction will facilitate the continued build out of our current portfolio and provide us with the corporate platform and strong financial position to build on our strength in men’s healthcare and enable expansion into new specialty therapeutic focus areas. The transaction aligns with Auxilium’s well-defined growth strategy and our intention to build a more diversified global organization through the aggressive pursuit of product licensing and M&A. We expect Auxilium to create increased value for shareholders and patients for years to come.”

QLT Retinoid Program

QLT’s synthetic retinoid program is a replacement for 11-cis-retinal and is under development for the treatment of retinal diseases caused by gene mutations that interfere with the availability of 11-cis-retinal. QLT has conducted safety and proof of concept clinical studies to evaluate its oral synthetic retinoid in patients with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP). The innovative ophthalmology program is nearing Phase 3 development. With its orphan drug designation, QLT’s synthetic retinoid program augments Auxilium’s existing orphan drug portfolio and allows Auxilium to expand its orphan drug reach outside of the U.S. Auxilium and QLT intend to continue to pursue discussions around a potential partnering agreement for this promising late-stage retinoid program.

Approvals and Further Details

The transaction, which has been unanimously approved by the Boards of both companies, is subject to certain conditions and approvals, including regulatory approvals in the U.S. and Canada, if necessary, the approval of both companies’ shareholders, consents under Auxilium’s senior secured credit facility required as a result of the transaction or, in lieu of such consents, the refinancing of such facility, receipt of an opinion of counsel to Auxilium that “New Auxilium” should not be treated as a U.S. domestic corporation for U.S. federal income tax purposes, and other negotiated closing conditions. Deutsche Bank has delivered a commitment letter for a $225 million facility for the refinancing of the senior secured credit facility (together with cash on hand) that is subject to the execution of definitive agreements and other conditions.  The transaction is expected to close in the fourth quarter of 2014, and is expected to be taxable to Auxilium shareholders. Holders representing approximately 32% of QLT shares outstanding have agreed to vote in favor of the transaction.

Deutsche Bank, Skadden Arps and Morgan Lewis acted as advisors to Auxilium. Houlihan Lokey Financial Advisors, Inc. also acted as an advisor to Auxilium. Credit Suisse, McCullough O’Connor Irwin LLP, Nutter McClennen & Fish LLP and KPMG LLP acted as advisors to QLT.

Conference Call
Auxilium will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m. ET. The presentation slides to be used during the call will be available on the “Investors” section of Auxilium’s web site under the “Presentations” tab at 8:30 a.m. ET. A question and answer session will follow the presentation. The conference call and the presentation slides will be simultaneously webcast on the “Investors” section of Auxilium’s website under the “Events” tab. The conference call will be archived via webcast for future review until July 26, 2014. Investors and other interested parties may call 866-510-0712 and enter passcode AUXILIUM. Please dial in 10 minutes prior to the scheduled start time.

About Auxilium
Auxilium Pharmaceuticals, Inc. is a fully integrated specialty biopharmaceutical company with a focus on developing and commercializing innovative products for specialist audiences. With a broad range of first- and second-line products across multiple indications, Auxilium is an emerging leader in the men’s healthcare area and has strategically expanded its product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas. The Company now has a broad portfolio of 12 approved products. Among other products in the U.S., Auxilium markets edex® (alprostadil for injection), an injectable treatment for erectile dysfunction, Osbon ErecAid®, the leading device for aiding erectile dysfunction, STENDRA® (avanafil), an oral erectile dysfunction therapy, Testim® (testosterone gel) for the topical treatment of hypogonadism, TESTOPEL® (testosterone pellets) a long-acting implantable testosterone replacement therapy, XIAFLEX® (collagenase clostridium histolyticum or CCH) for the treatment of Peyronie’s disease and XIAFLEX for the treatment of Dupuytren’s contracture. The Company also has programs in Phase 2 clinical development for the treatment of Frozen Shoulder syndrome and cellulite. To learn more, please visit

About QLT
QLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. QLT is focused on developing its synthetic retinoid program for the treatment of certain inherited retinal diseases. QLT’s head office is based in Vancouver, Canada and the Company is publicly traded on NASDAQ Stock Market (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT). For more information about the Company’s products and developments, please visit our web site at

No Offer or Solicitation
This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Additional Information
In connection with the proposed merger, QLT plans to file with the Securities and Exchange Commission (“SEC”) a Registration Statement on Form S-4 that will include a joint proxy statement of Auxilium and QLT that also constitutes a prospectus of QLT.  Auxilium and QLT will mail the joint proxy statement/prospectus to their respective stockholders. INVESTORS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION.  You will be able to obtain the joint proxy statement/prospectus, as well as other filings containing information about Auxilium and QLT, free of charge, at the website maintained by the SEC at and, in QLT’s case, also at the website maintained by the Canadian Securities Administrators (“CSA”) at You may also obtain these documents, free of charge, from Auxilium’s website ( under the heading “Investors – SEC Filings” or by directing a request to Auxilium, Attention: Investor Relations, 640 Lee Road, Chesterbrook, PA 19087. You may also obtain these documents, free of charge, from QLT’s website ( under the tab “Investors” and then under the headings “Securities Filings” and “Proxy Circulars” or by directing a request to QLT, Attention: Investor Relations, 887 Great Northern Way, Suite 250, Vancouver, BC, Canada, V5T 4T5.

Participants in the Solicitation
The respective directors and executive officers of Auxilium and QLT and other persons may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction.  Information regarding Auxilium’s directors and executive officers is available in its definitive proxy statement filed with the SEC by Auxilium on April 10, 2014, and information regarding QLT directors and executive officers is available in its Annual Report on Form 10-K/A filed with the SEC and applicable Canadian securities regulators by QLT on April 30, 2014. These documents can be obtained free of charge from the sources indicated above. Other information regarding the interests of the participants in the proxy solicitation will be included in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC and the applicable Canadian securities regulators when they become available.

Cautionary Statement Regarding Forward-Looking Statements
To the extent any statements made in this press release contain information that is not historical, these statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information as defined under applicable Canadian securities legislation (collectively, “forward-looking statements”).

These forward-looking statements relate to, among other things, the degree to which the transaction accelerates Auxilium’s ongoing transformation into a leading diversified North American specialty pharmaceutical company; whether the combined company’s profitability increases in the future; the degree to which the transaction enhances Auxilium’s growth profile, expands its geographic reach or the efficiencies of Auxilium’s platform to drive shareholder value creation through increased investments in research and development; whether Auxilium pursues or obtains a potential strategic or partnering agreement for QLT’s late-stage retinoid program; whether the transaction enables Auxilium to create a more competitive and efficient global platform, capitalize on greater market opportunities, positions Auxilium to deliver value for its shareholders, or enhances Auxilium’s ability to invest in or offer innovative products; whether this transaction will facilitate the continued build-out of Auxilium’s current portfolio and further build out its men’s healthcare portfolio and establish new specialty therapeutic areas; whether the reorganized company is positioned to achieve growth, sustained or otherwise; whether QLT or Auxilium shareholders will receive any of the anticipated benefits of the transaction; the degree to which the closing of the transaction results in any changes to Auxilium’s current U.S. operations or employment agreements, whether Auxilium will grow its presence in either the U.S. or Canada; whether QLT’s synthetic retinoid program augments Auxilium’s existing orphan drug portfolio or allows Auxilium to expand its orphan drug reach outside of the U.S.; when the transaction will close, if at all; completion of the various steps of the transaction including filing and mailing of the joint proxy statement/prospectus; the expected benefits of the proposed transaction such as efficiencies, cost savings, tax benefits, enhanced cash management flexibility, growth potential, market profile and financial strength; the tax consequences to shareholders; the competitive ability and position of the combined company; the expected timing of the completion of the transaction; whether the transaction will be taxable to Auxilium shareholders; or the securities exchange on which shares of the new parent company of Auxilium will trade. Forward-looking statements can generally be identified by the use of words such as “believe”, “anticipate”, “expect”,  “estimate”, “intend”, “continue”, “plan”, “project”, “will”, “may”, “should”, “could”, “would”, “target”, “potential” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Although certain of these statements set out herein are indicated above, all of the statements herein that contain forward-looking statements are qualified by these cautionary statements  Although Auxilium and QLT believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, including, but not limited to, factors and assumptions regarding the items outlined above. Actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things, the following: the failure to receive, on a timely basis or otherwise, the required approvals by Auxilium and QLT stockholders and government or regulatory agencies (including the terms of such approvals); the risk that a condition to closing of the merger may not be satisfied; the possibility that the anticipated benefits and synergies from the proposed merger cannot be fully realized or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of Auxilium and QLT operations will be greater than expected; the ability of Auxilium and QLT to obtain consents of lenders or to obtain refinancing in connection with the transaction, and if the transaction is consummated, the adequacy of the capital resources of “New Auxilium;” the ability of the combined company to retain and hire key personnel and maintain relationships with customers, suppliers or other business partners; the impact of legislative, regulatory, competitive and technological changes, including changes in tax laws or interpretations that could increase “New Auxilium’s” or Auxilium’s consolidated tax liabilities, including, if the transaction is consummated, changes in tax laws that would result in “New Auxilium” being treated as a domestic corporation for United States federal tax purposes; the risk that the credit ratings of the combined company may be different from what the companies expect; and other risk factors relating to the biopharmaceutical and medical device industries, or the business and operations of either of Auxilium or QLT as detailed from time to time in each of Auxilium’s and QLT’s reports filed with the SEC and, in QLT’s case, the applicable Canadian securities regulators.  There can be no assurance that the proposed merger will in fact be consummated. 

Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this press release, as well as under Item 1.A. in each of Auxilium’s and QLT’s respective Annual Reports on Form 10-K for the fiscal year ended December 31, 2013, and Item 1.A in each of Auxilium’s and QLT’s most recent Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2014.  Auxilium and QLT caution that the foregoing list of important factors that may affect future results is not exhaustive. When relying on forward-looking statements to make decisions with respect to Auxilium and QLT, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Neither QLT nor Auxilium undertakes any obligation to update or revise any forward-looking statement, except as may be required by law.

Auxilium Contacts:

Keri P. Mattox / SVP, IR & Corporate Communications
Auxilium Pharmaceuticals, Inc.
(484) 321-5900

Nichol L. Ochsner / Senior Director, IR & Corporate Communications
Auxilium Pharmaceuticals, Inc.
(484) 321-5900

For Media:
George Sard, David Reno, Alexandra LaManna
Sard Verbinnen and Co.
(212) 687-8080

QLT Contacts:
Investor & Media Relations
Andrea Rabney or David Pitts
Argot Partners
(212) 600-1902

Thursday, June 26th, 2014 Uncategorized Comments Off on (QLTI) to Merge with (AUXL)

(OHRP) Vista Partners Updates Coverage; Raises Price Target to $31

SAN FRANCISCO, CA–(Jun 26, 2014) – Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) (“The Company” or “OHR”) and raised its twelve month price target from $14 to $31. Ross Silver, Principal Analyst at Vista Partners, stated, “OHR is focused on developing Squalamine Eye Drops, currently in a Phase 2 trial, for the treatment of the wet form of age-related macular degeneration (Wet-AMD), a chronic eye disease that causes vision loss in the center of your field of vision. Therapies for Wet-AMD such as ranibizumab (Lucentis®) sold by Genentech (acquired by Roche), as well as Regeneron’s aflibercept (Eylea®) intravitreal injections, have become the market leaders in treating Wet-AMD and both therapies combined garnered approximately $6B of revenues in 2013. OHR’s Wet-AMD clinical candidate Squalamine eye drops showed gains in visual acuity according to the interim data presented Tuesday this week. The current forms of approved treatment, Lucentis® and Eylea®, require an injection into the back of the eye. Also in clinical development, Opthotech’s Fovista®, requires an injection into the back of the eye post an initial Lucentis® injection and is being developed to increase visual acuity. Squalamine Eye Drops would seem to present a significant advantage relative to the aforementioned therapy (Fovista®) considering Squalamine Eye Drops delivery method which is self-administered eye drops. Squalamine Eye Drops may have the potential to create a monumental shift in the way patients are treated for Wet-AMD if approved. The positive visual acuity results also provide a possible trajectory for a Phase 3 trial design.” Mr. Silver concludes, “OHR completed an equity financing of $18M in April 2014, which according to the Company, gives them a cash runway well into 2016.”

To download a FREE copy of the Ohr Pharmaceutical, Inc. research report, please visit and click the “Download Research” icon to gain access to the report.

About Vista Partners:

Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm’s professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing globally across all market sectors. Vista also provides investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista’s mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes.

Please follow us on Twitter @VistaPResearch & Facebook at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more.

Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website or click here.

Vista Partners LLC
Email Contact

Thursday, June 26th, 2014 Uncategorized Comments Off on (OHRP) Vista Partners Updates Coverage; Raises Price Target to $31

(VGGL) Adds Millions of Digital Rewards with Acquisition of Choose Digital

Viggle Inc. (NASDAQ: VGGL), the mobile entertainment marketing and rewards platform, announced today that it has acquired Choose Digital, a digital marketplace platform that allows companies to incorporate digital content into existing rewards and loyalty programs in support of marketing and sales initiatives.

With the acquisition, the Choose Digital platform will power digital media rewards for the Viggle platform, including music, audiobooks, TV and movies, enabling Viggle members to get free entertainment content just for enjoying their favorite TV shows and music.

Choose Digital works with all of the major music labels and top independents, offering millions of songs, albums and box sets through its platform. More than 300,000 books from three of the top publishing houses are available through Choose Digital as well. Streaming for tens of thousands of TV programs and movies is expected to launch in the coming months.

The Viggle Store – a rewards destination where members can redeem their Viggle Points for music downloads – is already powered by Choose Digital, which also powers the digital media rewards capabilities for leading loyalty programs at businesses such as Marriott, SkyMall and United Airlines.

Choose Digital was founded in 2011 and its management team brings a deep understanding of the loyalty industry, content industries and online retailing. Stephen Humphreys, Co-Founder and CEO, is a veteran of the loyalty and affinity marketing space with over 17 years of global experience. Mario Cruz, Co-Founder and CTO, has over 17 years of experience in IT, with a focus on high-volume transaction programs in the loyalty and rewards market, and has been awarded a patent in the space.

“The Choose Digital team has some of the deepest experience in loyalty programs, promotional marketing, rewards and technology,” said Greg Consiglio, COO of Viggle Inc. “With this acquisition, we can now develop end-to-end entertainment and loyalty rewards programs for our brand, TV network and music industry partners. We can identify the content our members watch or listen to and then issue relevant rewards though the Viggle Store. Our Viggle members benefit by redeeming their points for highly relevant digital content through our patented entertainment rewards platform.”

Choose Digital has built a unique and innovative “private label” digital marketplace that allows companies to incorporate digital content into their sales and marketing strategies. Its content, consisting of digital music, movies, TV shows, eBooks and audiobooks, is current, wide and sourced directly from global record companies, major studios, and publishers. New categories including apps, games, and magazines are currently under development. The market positioning of Choose Digital is agnostic – it has no consumer-facing brand, or any direct relationship with consumers.

“With the combined power of Viggle and Choose Digital technologies, we look forward to becoming the premier solution for brands to deliver digital rewards,” said Cruz, of Choose Digital.

Choose Digital joins Viggle Music and the Viggle Store as recent additions to the Viggle Platform, which includes Wetpaint, a leading entertainment destination for creating, curating and sharing the best entertainment content; NextGuide, which helps TV networks reach and engage their audiences; and the Viggle app, which rewards its members for watching their favorite TV shows as well as discovering new music. In March 2014, Viggle Inc. achieved a total reach of 20.8 million.

About Viggle Inc.

Viggle is an entertainment marketing and rewards platform whose app rewards its members for watching TV shows and discovering new music. The Viggle mobile app has over 4 million users. Since its launch, Viggler members have redeemed over $18 million in rewards for watching their favorite TV programs and listening to music. In addition, Viggle operates Wetpaint, which offers entertainment and celebrity news online. Viggle also operates Dijit Media, maker of technology that helps consumers search for, find, and set reminders for TV shows and movies. For more information, visit or follow us on Twitter @Viggle.

About Choose Digital

Founded by pioneers in the loyalty and incentive industry, Choose Digital is the first company to bring digital media as a point redemption option to the worldwide loyalty and incentive market. Choose Digital has partnerships with leading media companies to offer digital content – movies, TV shows, music, eBooks and audiobooks – via its turnkey marketplace for loyalty, incentive and frequent flyer programs. Headquartered in Miami, Florida, Choose Digital is a venture-backed company.

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. All information provided in this press release is as of June 25, 2014. Except as required by law, Viggle Inc. undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Wednesday, June 25th, 2014 Uncategorized Comments Off on (VGGL) Adds Millions of Digital Rewards with Acquisition of Choose Digital

(UNXL) Achieves Roll-to-Roll Pilot Production of InTouch Sensors

Company to Hold Conference Call at 4:30 PM ET Today

THE WOODLANDS, TX–(Jun 25, 2014) – UniPixel, Inc. (NASDAQ: UNXL), a provider of Performance Engineered Films™ to the touch screen, flexible printed electronics and display markets, has achieved roll-to-roll pilot production of its InTouch Sensors™, a projected capacitive, multi-touch sensor film.

Advancement Highlights

  • Achieved technical breakthrough in roll-to-roll plating process.
  • Transitioned from lab-based development to roll-to-roll pilot production.
  • Technical work streams now focused on ramping roll-to-roll manufacturing yields.

UniPixel has achieved a breakthrough in the roll-to-roll plating process, overcoming previously reported challenges through modification of hardware and chemistry configurations. The new process conditions have been successfully demonstrated in the roll-to-roll pilot production process, achieving a step-change improvement in plating fine-line conductive elements on its touch sensor film.

The company now has a fully-functional, roll-to-roll pilot production line comprised of a plating line at the company’s Texas facility, and printing, final testing and packaging at the Kodak facility, a state-of-the-art manufacturing and testing facility within the Eastman Business Park in Rochester, New York. UniPixel and Kodak have begun conducting roll-to-roll pilot manufacturing and yield studies on the overall process, as well as technology transfer of the modified process to production plating assets in the Kodak facility.

“Since our last quarterly report in May, our teams have made tremendous progress in further advancing our roll-to-roll printing manufacturing process, finalizing the ink and substrate, and resolving the major roll-to-roll plating technical challenges,” said Jeff Hawthorne, president and CEO of UniPixel. “Having achieved roll-to-roll pilot production capability, we are now focused on ramping overall product yields, as well as utilizing the pilot line to scale hardware, processes and manufacturing procedures, and to validate product quality criteria for volume production.”

To reduce development complexity and speed the time-to-market of UniPixel’s first InTouch Sensors Powered by Kodak product, UniPixel and Kodak technical work streams have been primarily focused on an initial development project for the tablet market and working closely with a certain tablet manufacturer. According to DisplaySearch, the tablet sensor segment is growing at 9% CAGR to 448 million units shipped annually by 2018.

UniPixel continues to make progress on the newly established product and technology development roadmap that next addresses the larger form factor, all-in-one PC market. The company is running concurrent development projects to support release of an all-in-one touch sensor product.

In addition to making progress with its roll-to-roll touch sensor manufacturing process, the company has advanced its Diamond Guard™ hard-coat resin technology. UniPixel has successfully coated PET film with Diamond Guard hard-coat resin at a pilot production coating facility using production-length film coating trial runs. The company continues to work to scale resin and coating technology to a full production quality, film product. Diamond Guard’s pilot coating ranges from 4H to 6H hardness levels, as compared to most hard coat alternatives that range from 2H to 3H. The Diamond Guard coating performance attributes have generated attention from a number of coaters who are interested in working with the company.

The company plans to provide an update on the progress towards achieving volume touch sensor production in the second half of 2014 during the upcoming second quarter earnings call in early August.

Conference Call
UniPixel management will host a conference call later today to discuss its operational progress.

The call will be webcast live here, as well as via a link in the Investors section of the company’s website at Webcast participants will be able to submit a question to management via the webcast player.

Date: Wednesday, June 25, 2014
Time: 4:30 p.m. Eastern time (3:30 p.m. Central time)

To participate in the conference call via telephone, dial 1-719-457-2617 and provide the conference name or conference ID 9530358. Please call the conference telephone number five minutes prior to the start time so the operator can register your name and organization.

If you have any difficulty with the webcast or connecting to the call, please contact Liolios Group at 1-949-574-3860.

A replay of the call will be available after 7:30 p.m. Eastern time on the same day through July 25, 2014, via the same link above, or by dialing 1-858-384-5517 and entering replay ID 9530358.

About UniPixel
Headquartered in The Woodlands, Texas, UniPixel, Inc. (NASDAQ: UNXL) delivers Performance Engineered Films to the Display and Flexible Electronics markets. UniPixel’s high-volume roll-to-roll or continuous flow manufacturing process offers high-fidelity replication of advanced micro-optic structures and surface characteristics over large areas. A key focus for UniPixel is developing electronic conductive films for use in electronic sensors for consumer and industrial applications. The company’s roll-to-roll electronics manufacturing process prints fine line conductive elements on thin films. The company is marketing its films for touch panel sensor, cover glass replacement, protective cover film, antenna and custom circuitry applications under the UniPixel label, and potentially under private label or Original Equipment Manufacturers (OEM) brands. For further information, visit

Forward-looking Statements
All statements in this news release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the companies’ respective Annual Report on Form 10-K for the year ended December 31, 2013. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the companies’ respective Annual Report on Form 10-K, quarterly reports on Form 10-Q and Current Reports on Form 8-K.

Trademarks in this release are the property of their respective owners.

Investor Relations Contact:
Ron Both
Liolios Group, Inc.
Tel 949-574-3860
Email Contact

Wednesday, June 25th, 2014 Uncategorized Comments Off on (UNXL) Achieves Roll-to-Roll Pilot Production of InTouch Sensors